Inventurus Knowledge Solutions Ltd
Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]
- Market Cap ₹ 27,022 Cr.
- Current Price ₹ 1,575
- High / Low ₹ 2,190 / 1,226
- Stock P/E 55.5
- Book Value ₹ 104
- Dividend Yield 0.00 %
- ROCE 27.2 %
- ROE 33.0 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 28.8% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 37.0%
Cons
- Stock is trading at 15.0 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: IT - Software Industry: Computers - Software - Medium / Small
Part of BSE Information Technology Nifty 500 BSE MidCap BSE IPO Nifty Smallcap 100
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
529 | 553 | 764 | 1,031 | 1,818 | 2,664 | |
367 | 348 | 466 | 639 | 1,297 | 1,894 | |
Operating Profit | 162 | 205 | 298 | 392 | 521 | 770 |
OPM % | 31% | 37% | 39% | 38% | 29% | 29% |
31 | 16 | 1 | -2 | 40 | 39 | |
Interest | 7 | 8 | 7 | 6 | 61 | 90 |
Depreciation | 40 | 30 | 23 | 25 | 59 | 113 |
Profit before tax | 145 | 183 | 269 | 359 | 442 | 606 |
Tax % | 5% | 9% | 13% | 15% | 16% | 20% |
137 | 165 | 233 | 305 | 370 | 486 | |
EPS in Rs | 166.73 | 200.10 | 13.61 | 17.86 | 21.68 | 28.33 |
Dividend Payout % | 0% | 12% | 393% | 0% | 46% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 38% |
3 Years: | 52% |
TTM: | 47% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 29% |
3 Years: | 25% |
TTM: | 31% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 39% |
3 Years: | 37% |
Last Year: | 33% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 17 | 17 | 17 | 17 |
Reserves | 275 | 449 | 630 | 812 | 1,141 | 1,773 |
0 | 76 | 65 | 52 | 1,311 | 856 | |
151 | 53 | 75 | 107 | 411 | 407 | |
Total Liabilities | 434 | 586 | 788 | 988 | 2,880 | 3,052 |
36 | 87 | 76 | 59 | 1,833 | 1,798 | |
CWIP | 0 | 0 | 0 | 0 | 3 | 5 |
Investments | 1 | 14 | 16 | 32 | 195 | 114 |
397 | 485 | 695 | 898 | 849 | 1,135 | |
Total Assets | 434 | 586 | 788 | 988 | 2,880 | 3,052 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
163 | 175 | 233 | 288 | 210 | 318 | |
-79 | -167 | -82 | -158 | -1,137 | 244 | |
-41 | -37 | -59 | -152 | 780 | -389 | |
Net Cash Flow | 43 | -28 | 92 | -22 | -147 | 173 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 51 | 49 | 46 | 57 | 73 | 73 |
Inventory Days | ||||||
Days Payable | ||||||
Cash Conversion Cycle | 51 | 49 | 46 | 57 | 73 | 73 |
Working Capital Days | 20 | 48 | 21 | 26 | 6 | 46 |
ROCE % | 47% | 47% | 50% | 30% | 27% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16h - Inventurus to attend Nomura Forum Asia June 3-4, sharing prior investor presentation.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16h - The officials of the Company shall be attending the below mentioned Conference: Day, Date and Time: Thursday, May 29, 2025, from 10:00 AM IST to …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 May - Newspaper Publication - Extract of Financial Results enclosed.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
16 May - Audio recording of Q4 FY 2024-25 earnings call made available on company website.
-
Appointment Of Secretarial Auditor
15 May - Approved FY25 audited results with clean opinion; appointed Secretarial Auditor for 2025-30, subject to shareholder approval.
Concalls
-
May 2025TranscriptNotesPPT
-
Feb 2025Transcript PPT
Business Overview:[1]
IKSL is a technology-enabled healthcare solutions provider which offer a care enablement platform assisting physician enterprises in the US, Canada and Australia, with a focus on the US markets. It partners with an outpatient and inpatient health care organizations, enabling them to deliver superior clinical care through a **fee for value model **